Prediction of drug clearance in a smoking population: Modeling the impact of variable cigarette consumption on the induction of CYP1A2

European Journal of Clinical Pharmacology

Volumn 68, Issue 6, 2012, Pages 951-960

  Plowchalk, David R ^a   Rowland Yeo, Karen ^b  

^a PFIZER INC   (United States)

^b CERTARA UK LIMITED   (United Kingdom)

Author keywords

Caffeine; Clozapine; CYP1A2; Induction; Modeling; Smoking; Theophylline

Indexed keywords

CAFFEINE; CLOZAPINE; CYTOCHROME P450 1A2; PF 2400013; THEOPHYLLINE;

ADULT; ARTICLE; CIGARETTE SMOKING; COMPUTER MODEL; COMPUTER SIMULATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYP1A2 GENE; DRUG ADMINISTRATION ROUTE; DRUG CLEARANCE; DRUG METABOLISM; DRUG TARGETING; FEMALE; GENE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PHARMACOGENETICS; PREDICTIVE VALUE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; CAFFEINE; CLOZAPINE; COMPUTER SIMULATION; CYTOCHROME P-450 CYP1A2; ENZYME INDUCTION; FEMALE; HUMANS; LIVER; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; SEROTONIN 5-HT2 RECEPTOR AGONISTS; SMOKING; THEOPHYLLINE; YOUNG ADULT;

EID: 84864282147     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-011-1189-y     Document Type: Article

References (36)

1. Faber MS, Jetter A, Fuhr U (2005) Assessment of CYP1A2 activity in clinical practice: why, how, and when? Basic Clin Pharmacol Toxicol 97(3):125-134 (Pubitemid 41291208)
2. Ma Q, Lu AY (2003) Origins of individual variability in P4501A induction. Chem Res Toxicol 16(3):249-260 (Pubitemid 36373689)
3. Gunes A, Dahl ML (2008) Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms. Pharmacogenomics 9(5):625-637 (Pubitemid 351803920)
4. Schweikl H, Taylor JA, Kitareewan S, Linko P, Nagorney D, Goldstein JA (1993) Expression of CYP1A1 and CYP1A2 genes in human liver. Pharmacogenetics 3(5):239-249 (Pubitemid 23333093)
5. Carrillo JA, Herraiz AG, Ramos SI, Gervasini G, Vizcaino S, Benitez J (2003) Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. J Clin Psychopharmacol 23(2):119-127 (Pubitemid 36368788)
6. Obase Y, Shimoda T, Kawano T, Saeki S, Tomari SY, Mitsuta IK, Matsuse H, Kinoshita M, Kohno S (2003) Polymorphisms in the CYP1A2 gene and theophylline metabolism in patients with asthma. Clin Pharmacol Ther 73(5):468-474 (Pubitemid 36549830)
7. Sachse C, Bhambra U, Smith G, Lightfoot TJ, Barrett JH, Scollay J, Garner RC, Boobis AR, Wolf CR, Gooderham NJ, Colorectal Cancer Study G (2003) Polymorphisms in the cytochrome P450 CYP1A2 gene CYP1A2 in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism. Br J Clin Pharmacol 55(1):68-76 (Pubitemid 36110841)
8. Van der Weide J, Steijns LS, van Weelden MJ (2003) The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement. Pharmacogenetics 13 (3):169-172 (Pubitemid 36324246)
9. Dobrinas M, Cornuz J, Oneda B, Kohler Serra M, Puhl M, Eap CB (2011) Impact of smoking, smoking cessation, and genetic polymorphisms on CYP1A2 activity and inducibility. Clin Pharmacol Ther 90 (1):117-125
10. Bondolfi G, Morel F, Crettol S, Rachid F, Baumann P, Eap CB (2005) Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patients. Therapeutic Drug Monit 27(4):539-543 (Pubitemid 41098833)
11. Haslemo T, Eikeseth PH, Tanum L, Molden E, Refsum H (2006) The effect of variable cigarette consumption on the interaction with clozapine and olanzapine. Eur J Clin Pharmacol 62(12):1049-1053 (Pubitemid 44786497)
12. McCarthy RH (1994) Seizures following smoking cessation in a clozapine responder. Pharmacopsychiatry 27(5):210-211 (Pubitemid 24291953)
13. Bigos KL, Pollock BG, Coley KC, Miller DD, Marder SR, Aravagiri M, Kirshner MA, Schneider LS, Bies RR (2008) Sex, race, and smoking impact olanzapine exposure. J Clin Pharmacol 48(2):157-165
14. FDA (2003) Guidance document: exposure-response relationships - study design, data analysis and final regulatory applications
15. EMA (2010) Draft guidance on drug interactions
16. Edginton AN, Willmann S (2008) Physiology-based simulations of a pathological condition: prediction of pharmacokinetics in patients with liver cirrhosis. Clin Pharmacokinet 47(11):743-752
17. Johnson TN, Boussery K, Rowland-Yeo K, Tucker GT, Rostami-Hodjegan A (2010) A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance. Clin Pharmacokinet 49(3):189-206
18. Houston JB (1994) Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 47 (9):1469-1479 (Pubitemid 24167255)
19. Howgate EM, Rowland Yeo K, Proctor NJ, Tucker GT, Rostami-Hodjegan A (2006) Prediction of in vivo drug clearance from in vitro data. I. Impact of inter-individual variability. Xenobiotica 36 (6):473-497 (Pubitemid 43890728)
20. Jamei M, Marciniak S, Feng K, Barnett A, Tucker G, Rostami-Hodjegan A (2009) The Simcyp population-based ADME simulator. Expert Opinion Drug Metab Toxicol 5(2):211-223
21. Jamei M, Dickinson GL, Rostami-Hodjegan A (2009) A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recognition of covariates. [Review] [150 refs] [Erratum appears in Drug Metab Pharmacokinet. 2009; 24(5):488]. Drug Metab Pharmacokinet 24 (1):53-75
22. Rowland-Yeo K, Rostami-Hodjegan A, Tucker GT (2004) Abundance of cytochrome P450 in human liver: a meta-analysis. Br J Clin Pharmacol 57(5):687
23. Barter ZE, Bayliss MK, Beaune PH, Boobis AR, Carlile DJ, Edwards RJ, Houston JB, Lake BG, Lipscomb JC, Pelkonen OR, Tucker GT, Rostami-Hodjegan A (2007) Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. [Review] [80 references]. Curr Drug Metabol 8(1):33-45 (Pubitemid 46043890)
24. Johnson TN, Tucker GT, Tanner MS, Rostami-Hodjegan A (2005) Changes in liver volume from birth to adulthood: a meta-analysis. Liver Transpl 11(12):1481-1493 (Pubitemid 43072624)
25. Parkinson A, Mudra DR, Johnson C, Dwyer A, Carroll KM (2004) The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol 199(3):193-209 (Pubitemid 39208721)
26. Tantcheva-Poór I, Zaigler M, Rietbrock S, Fuhr U (1999) Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test. Pharmacogenetics 9 (2):131-144 (Pubitemid 29358995)
27. Blanchard J, Sawers SJ (1983) The absolute bioavailability of caffeine in man. Eur J Clin Pharmacol 24(1):93-98 (Pubitemid 13181790)
28. Terziivanov D, Bozhinova K, Dimitrova V, Atanasova I (2003) Nonparametric expectation maximisation (NPEM) population pharmacokinetic analysis of caffeine disposition from sparse data in adult Caucasians: systemic caffeine clearance as a biomarker for cytochrome P450 1A2 activity. Clin Pharmacokinet 42(15):1393-1409 (Pubitemid 38045843)
29. Hunt SN, Jusko WJ, Yurchak AM (1976) Effect of smoking on theophylline disposition. Clin Pharmacol Ther 19(5 Pt 1):546-551
30. Gardner MJ, Tornatore KM, Jusko WJ, Kanarkowski R (1983) Effects of tobacco smoking and oral contraceptive use on theophylline disposition. Br J Clin Pharmacol 16(3):271-280 (Pubitemid 13043513)
31. Jennings TS, Nafziger AN, Davidson L, Bertino JS Jr (1993) Gender differences in hepatic induction and inhibition of theophylline pharmacokinetics and metabolism. J Lab Clin Med 122 (2):208-216 (Pubitemid 23239153)
32. Seppälä NH, Leinonen EV, Lehtonen ML, Kivistö KT (1999) Clozapine serum concentrations are lower in smoking than in non-smoking schizophrenic patients. Pharmacol Toxicol 85 (5):244-246
33. Rostami HA, Amin AM, Spencer EP, Lennard MS, Tucker GT, Flanagan RJ (2004) Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J Clin Psychopharmacol 24(1):70-78 (Pubitemid 38134168)
34. Palego L, Biondi L, Giannaccini G, Sarno N, Elmi S, Ciapparelli A, Cassano GB, Lucacchini A, Martini C, Dell OL (2002) Clozapine, norclozapine plasma levels, their sum and ratio in 50 psychotic patients: influence of patient-related variables. Prog Neuropsychopharmacol Biol Psychiatry 26(3):473-480 (Pubitemid 34252940)
35. Rostami-Hodjegan A, Kroemer HK, Tucker GT (1999) In-vivo indices of enzyme activity: the effect of renal impairment on the assessment of CYP2D6 activity. Pharmacogenetics 9 (3):277-286 (Pubitemid 29376371)
36. Djordjevic N, Ghotbi R, Bertilsson L, Jankovic S, Aklillu E (2008) Induction of CYP1A2 by heavy coffee consumption in Serbs and Swedes. Eur J Clin Pharmacol 64(4):381-385 (Pubitemid 351322359)